Kanabo Group (LSE:KNB) Momentum Rank : 0 (As of Jun. 20, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kanabo Group Momentum Rank?

Kanabo Group has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Kanabo Group Momentum Rank Related Terms

Thank you for viewing the detailed overview of Kanabo Group's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Kanabo Group (LSE:KNB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Kanabo Group PLC (LSE:KNB) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

3WD:Germany

Address

137-139 Brent Street, Churchill House, London, GBR, NW4 4DJ

Website

https://www.kanabogroup.com

Kanabo Group PLC is a research and development company engaged in selling a range of THC-Free retail CBD products in the markets and it is in the process of developing medical cannabis products. Its reportable segments include Primary Care and Secondary Care. The Primary Care segment includes Tele pharma services provided by GPS and The Secondary Care segment includes the development and distribution of cannabis-derived medical and wellness products. Geographically company has a presence in the United Kingdom, Israel, and others.

Kanabo Group (LSE:KNB) Headlines

No Headlines